CASE STUDY: STRATEGY

Working with advocacy groups to redefine outcomes measures

Challenge

A patient advocacy organization-led brain health coalition was organized to redefine measurement outcomes for people living with a rare disease that results in cognitive delays and limitations. In this coalition of 50+ advocacy groups and industry members, Agency presence was lacking.

Solution

Identifying where our client could provide value to the coalition, we engaged their Regulatory partner. Together, we determined that a Critical Path Innovation meeting would be the next best step.

Impact

The coalition was excited by the opportunity to redefine the measurement space in partnership with FDA, and the reputational benefit to the biotech was immediate.